✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Best Glaucoma Eye Drops in 2026: 10 Evidence-Backed Picks for Lowering Intraocular Pressure

Glaucoma is the second-leading cause of irreversible blindness worldwide, but the disease is highly treatable when caught early and managed consistently. The unifying treatment goal is to lower intraocular pressure (IOP) by 20–30% from baseline — the only modifiable risk factor with strong evidence to slow optic nerve damage. Modern glaucoma management is built almost entirely on topical eye drops; surgery (laser trabeculoplasty, MIGS, trabeculectomy) is reserved for drop-resistant cases.

This guide ranks the 10 glaucoma eye drops most worth knowing about in 2026. The mix covers all five major IOP-lowering classes — prostaglandin analogues (the first-line standard), beta-blockers, alpha-2 agonists, carbonic anhydrase inhibitors, and miotics — plus the best-evidence fixed-dose combinations that simplify regimens when monotherapy isn’t enough. Each pick links to a full product page; the comparison table after the picks is the centerpiece for skim readers.

• Table of Contents

  • How glaucoma drops lower IOP
  • The 10 picks (ranked)
  • Comparison table
  • Decision shortcut
  • Drop instillation technique that actually matters
  • Safety, side effects, and contraindications
  • FAQs
  • Bottom line

How glaucoma drops lower IOP

IOP is the balance of aqueous humour production (by the ciliary body) and outflow (through the trabecular meshwork and uveoscleral pathway). The five drug classes target different limbs:

• Prostaglandin analogues — latanoprost, travoprost, bimatoprost, tafluprost. Increase uveoscleral outflow. Most powerful class (~25–33% IOP reduction); once-daily HS dosing. First-line for most patients.
• Beta-blockers — timolol, betaxolol. Decrease aqueous production. ~20–25% IOP reduction; twice-daily dosing (or once-daily with gel-forming formulations). Avoid in asthma, COPD, bradycardia, advanced AV block.
• Alpha-2 agonists — brimonidine, apraclonidine. Decrease aqueous production AND increase uveoscleral outflow. ~20% IOP reduction; BID-TID dosing. Allergic conjunctivitis is the main side effect.
• Carbonic anhydrase inhibitors (CAI) — brinzolamide, dorzolamide (topical); acetazolamide (oral, for severe acute IOP elevation). Decrease aqueous production. ~15–20% IOP reduction; BID-TID dosing.
• Miotics / cholinergics — pilocarpine. Increase trabecular outflow by physically opening the angle. ~15–20% IOP reduction; QID dosing. Largely superseded by other classes for primary open-angle glaucoma but still essential in angle-closure situations and certain MIGS contexts.

The standard treatment ladder: start with a prostaglandin analogue. If IOP target isn’t met, add (don’t replace) a beta-blocker or alpha-2 agonist. If target still isn’t met, add a CAI or move to a fixed-dose combination drop to reduce drop burden. After 3 drops daily, consider laser trabeculoplasty or surgical options.

The 10 picks (ranked)

1. Xalatan (latanoprost 0.005%) — the gold-standard first-line glaucoma drop

Latanoprost is the most-prescribed glaucoma drop worldwide and the established first-line agent for primary open-angle glaucoma and ocular hypertension. One drop in the affected eye(s) at bedtime lowers IOP by ~25–33% within 4 weeks of starting. Cosmetic side effects (gradual iris darkening, eyelash lengthening / thickening / darkening, periorbital fat atrophy with chronic use) are common but mostly cosmetic. Refrigerate before opening; can be at room temperature once opened. Buy Xalatan.

2. Travatan (travoprost 0.004%) — alternative prostaglandin with slightly higher IOP-lowering in some patients

Travoprost is the alternative prostaglandin analogue often preferred when latanoprost gives insufficient IOP lowering — in head-to-head trials travoprost gives 1–2 mmHg additional reduction in some patients. Same once-nightly dosing, same cosmetic side-effect profile (iris pigmentation, eyelash changes, periorbital fat atrophy). Travoprost has a slightly higher rate of mild conjunctival hyperaemia than latanoprost but the cardiovascular safety profile is identical (essentially nil at topical doses). Buy Travatan.

3. Lumigan (bimatoprost 0.03% / 0.01%) — the prostaglandin amide with the strongest IOP-lowering of the class

Bimatoprost is a prostamide (prostaglandin amide) with the highest mean IOP-lowering of any prostaglandin in head-to-head trials — 1–2 mmHg better than latanoprost or travoprost on average. The 0.01% formulation has lower rates of conjunctival hyperaemia than the original 0.03% with similar IOP efficacy and is now first-line for new bimatoprost prescriptions. The eyelash growth side effect was strong enough that the same molecule was repackaged commercially as Latisse for cosmetic eyelash enhancement. Buy Lumigan.

4. Iotim (timolol 0.5%) — the workhorse beta-blocker, second-line add-on

Timolol is the original glaucoma beta-blocker (in market since 1978) and remains the standard add-on when a prostaglandin alone doesn’t reach IOP target. One drop twice daily lowers IOP by ~20–25%. The most important practical safety point: even topical timolol absorbs systemically through the nasolacrimal duct enough to cause bronchospasm in asthma, bradycardia, hypotension, and worsening of heart failure — so punctal occlusion after instillation is essential, and timolol should be avoided in patients with reactive airway disease, second/third-degree heart block, or symptomatic bradycardia. Buy Iotim.

5. Azopt (brinzolamide 1%) — the topical CAI for additional IOP lowering

Brinzolamide is the topical carbonic anhydrase inhibitor used as a third-line add-on or as second-line in patients where beta-blockers are contraindicated. One drop two to three times daily lowers IOP by ~15–20%. The 1% suspension is generally less stinging than dorzolamide 2% solution — useful for patients with sensitive eyes. Avoid in patients with sulfa allergy (CAIs are sulfonamide derivatives, though clinically significant cross-reactivity is rare). Buy Azopt.

6. Alphagan P (brimonidine 0.1% / 0.15%) — the alpha-2 agonist add-on with the cleanest CV safety profile

Brimonidine is the alpha-2 adrenergic agonist used as second-line in patients where beta-blockers are contraindicated (asthma, COPD, bradycardia). One drop two to three times daily lowers IOP by ~20%. The newer 0.1% and 0.15% formulations (Alphagan P) cause less ocular allergy than the original 0.2%. The main side effects are fatigue, dry mouth, and ocular allergic conjunctivitis (the “follicular reaction” that develops 6–12 months into therapy in 10–25% of patients). Don’t use in children <2 years (CNS depression risk). Buy Alphagan P.

7. Combigan (brimonidine 0.2% + timolol 0.5%) — the fixed-dose combination for two-drug therapy in one bottle

Combigan combines an alpha-2 agonist and a beta-blocker in one drop — right choice for patients who need both classes and whose target IOP isn’t met by prostaglandin + monotherapy add-on. One drop twice daily replaces two separate bottles dosed at different times. Fixed-dose combos consistently improve adherence vs separate-bottle regimens because they reduce drop burden and total preservative exposure to the ocular surface. Same beta-blocker contraindications apply (asthma, COPD, bradycardia, heart block). Buy Combigan.

8. Dorzox T (dorzolamide 2% + timolol 0.5%) — the CAI + beta-blocker combo for two-drug therapy

Dorzox T combines a topical carbonic anhydrase inhibitor and a beta-blocker in one drop — the third commonly-used fixed-dose combination after Combigan. One drop twice daily replaces two separate bottles. Right choice for patients who’ve responded better to dorzolamide than brimonidine on the CAI / alpha-2 second-line trial. Same beta-blocker safety considerations apply — punctal occlusion essential, avoid in reactive airway disease and bradycardia. Buy Dorzox T.

9. Bimat with Brush (bimatoprost 0.03% with applicator) — bimatoprost with cosmetic eyelash applicator

Bimat with Brush is bimatoprost 0.03% packaged with a fine cosmetic-grade applicator brush. Marketed primarily for the cosmetic eyelash-enhancement use case (the original mechanism behind Latisse) but the molecule is identical to bimatoprost glaucoma drops. For pure glaucoma management, the standard ophthalmic formulation (Lumigan) is the right choice; this product is most relevant when patients want both the IOP-lowering and the cosmetic eyelash benefit, or for off-label cosmetic use only. Buy Bimat with Brush.

10. Pilocar (pilocarpine 1% / 2% / 4%) — the miotic for angle-closure and select MIGS contexts

Pilocarpine is the cholinergic agonist that constricts the pupil and physically opens the iridocorneal angle. Largely superseded by other classes for primary open-angle glaucoma (older, four-times-daily dosing, brow ache, vision dimming in low light, accommodative spasm in younger patients), but remains essential in two scenarios: (1) acute angle-closure crisis as part of the IOP-lowering combination (along with topical beta-blocker, topical CAI, oral acetazolamide, sometimes IV mannitol) until laser peripheral iridotomy can be performed, and (2) certain trabecular bypass MIGS settings where miosis improves outflow. Newer low-concentration pilocarpine (1.25%) is also used cosmetically for presbyopia (Vuity in the US) but that’s a separate use case. Buy Pilocar.

Comparison table

Drop instillation technique that actually matters

Glaucoma drops only work if they get into the eye in the right amount. Most patients (and many clinicians) instil drops poorly. The technique that maximises ocular drug delivery and minimises systemic absorption:

1. Wash hands. Tilt head back. Pull lower lid down to form a pocket.
2. Hold the bottle 2–3 cm above the eye. Don’t touch the dropper to the eye, lashes, or skin (contamination risk).
3. One drop only. The conjunctival sac holds ~7 µL; one drop is ~30 µL. Two drops just overflow — you waste medication and increase systemic absorption.
4. Close the eye gently for 1–2 minutes. Don’t squeeze or blink rapidly — that pumps drug down the nasolacrimal duct and into systemic circulation.
5. Punctal occlusion: press the inner corner of the eye (where the tear duct opens) with a finger for 1–2 minutes. This blocks drug from draining into the nose and being absorbed systemically — especially important with timolol (cardiovascular safety) and brimonidine (CNS effects).
6. Wait 5+ minutes between different drops. Instilling two drops back-to-back washes the first one out before it can absorb.
7. Drops first, ointment last if you use both in the same eye.

Patients consistently underestimate the importance of these steps. Punctal occlusion alone increases ocular drug bioavailability by ~50%, which means the same dose works better and systemic side effects are dramatically reduced.

Safety, side effects, and contraindications

Prostaglandin analogue side effects (Xalatan, Travatan, Lumigan):

• Iris pigmentation (gradual darkening of the iris over months to years — permanent, more noticeable with mixed-color irides)
• Eyelash growth (longer, thicker, darker)
• Periorbital fat atrophy / sunken eye appearance with chronic use
• Conjunctival hyperaemia (redness)
• Caution in active uveitis, cystoid macular oedema, or recent intraocular surgery (rare association with macular oedema)

Beta-blocker side effects (Iotim, Combigan, Dorzox T):

• Bronchospasm in reactive airway disease
• Bradycardia, AV block worsening
• Worsening heart failure
• Masking of hypoglycaemia in diabetes
• Reduced exercise tolerance
• Depression, fatigue (less common at topical doses but reported)

Alpha-2 agonist side effects (Alphagan P, Combigan):

• Allergic conjunctivitis (the “6–12 month follicular reaction”)
• Dry mouth, dry eye
• Fatigue, sedation
• CNS depression (especially in children — contraindicated <2 years)
• Rebound mydriasis if abruptly stopped

CAI side effects (Azopt, Dorzox T):

• Bitter taste in the mouth (drainage through nasolacrimal duct)
• Stinging on instillation (less with brinzolamide than dorzolamide)
• Caution in sulfa allergy (sulfonamide structural similarity, though clinical cross-reactivity rare)
• Caution in severe hepatic or renal impairment

Pilocarpine side effects:

• Brow ache (most patients in the first 2–4 weeks; usually settles)
• Vision dimming in low light (constricted pupil)
• Accommodative spasm (especially troublesome in younger patients)
• Increased risk of retinal detachment in high myopia

Frequently Asked Questions

Why do I need to take glaucoma drops if I can’t feel anything?

Open-angle glaucoma damages the optic nerve silently — vision loss happens in the peripheral field first and is usually not noticed until 30–40% of nerve fibres are gone, by which point the damage is irreversible. The whole point of treatment is to prevent vision loss before it happens. Once peripheral vision is lost, no drop can bring it back. The drops feel like nothing because they’re working — the disease itself feels like nothing until it’s too late.

What’s my target IOP?

Target IOP is individualised based on the optic nerve damage at diagnosis, baseline IOP, and progression rate. The general goal is to reduce IOP by 20–30% from baseline. For patients with normal-tension glaucoma, baseline IOP may already be in the “normal” range (10–21 mmHg) but the optic nerve is still being damaged — the target is then ~30% below their baseline (e.g., 12 mmHg if baseline is 17). Your ophthalmologist will set and adjust the target based on visual field and OCT progression.

Will my iris really change colour from latanoprost?

Yes — about 5–15% of patients on latanoprost (or other prostaglandins) experience gradual iris darkening over months to years. The change is most visible in mixed-colour irides (e.g., hazel, blue-brown) and almost imperceptible in already-dark irides. The pigmentation is permanent (it doesn’t reverse if you stop the drop). Cosmetically significant change is rare; most patients don’t notice it.

Can I use my contact lenses with glaucoma drops?

Yes, but with care. Most glaucoma drops contain benzalkonium chloride (BAK) preservative, which absorbs into soft contact lenses and can cause ocular surface irritation over time. The standard recommendation: instil drops, wait 15 minutes, then insert contact lenses. Preservative-free formulations (some brands of latanoprost, tafluprost) are an option for patients who can’t tolerate BAK long-term.

How long until I know if my drop is working?

Prostaglandin analogues reach maximum IOP-lowering at 3–5 weeks of consistent dosing. Beta-blockers and alpha-2 agonists work within 1–2 weeks. CAIs work within 1 week. The standard recheck is at 4–6 weeks of starting any new glaucoma drop.

What happens if I miss a dose?

For prostaglandin analogues (once-nightly), if you remember within a few hours, take the dose; if it’s the next morning already, skip and resume the next night — don’t double up. For BID drops, take the missed dose if it’s within 4 hours of the missed time; otherwise skip. The bigger picture: missed doses are the single most important predictor of glaucoma progression. Set up reminders, calendar alerts, partner check-ins — whatever it takes to maintain consistent use.

Do I need to refrigerate my drops?

Latanoprost (Xalatan) requires refrigeration before opening to maintain potency; once opened, room temperature is fine. Travoprost and bimatoprost don’t require refrigeration. All glaucoma drops should be discarded 28 days after opening (preservative effectiveness drops, contamination risk increases) regardless of how much fluid is left.

What about laser treatment instead of drops?

Selective laser trabeculoplasty (SLT) is increasingly used as first-line treatment for newly-diagnosed POAG — the LiGHT trial showed equivalent IOP control to drops at 3 years with better quality of life. SLT is a clinic-based procedure, takes 15 minutes, lasts 2–5 years, and can be repeated. Discuss with your ophthalmologist if drop adherence is challenging or you’d prefer to avoid lifelong daily medication.

Bottom line

For newly diagnosed primary open-angle glaucoma or ocular hypertension, the consensus first-line is a once-nightly prostaglandin analogue: Xalatan (latanoprost) is the standard, with Lumigan (bimatoprost) preferred when stronger IOP-lowering is needed. Travatan (travoprost) is the third option in the same class.

When a prostaglandin alone doesn’t reach target, add (don’t replace) a second class: Iotim (timolol) for patients without asthma/COPD/HF, or Alphagan P (brimonidine) when beta-blockers are contraindicated. Third-line is Azopt (brinzolamide). For two-drug therapy in one bottle, Combigan or Dorzox T reduce drop burden and improve adherence.

The two practical points that matter most: drop technique (one drop, eye closed gently, punctal occlusion for 1–2 minutes — doubles the effective dose and reduces systemic side effects) and adherence (set reminders, partner check-ins, fixed-dose combos when on multiple drops — missed doses translate directly to optic nerve damage).

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.